In 2020, pharmaceutical executives will be highly variable, with more than 180 executives leaving

"Pharmaceutical network industry dynamics" recently, Sansheng Guojian issued a notice that the company's deputy general manager Yu Hua recently resigned from his position as deputy general manager for personal reasons, from now on no longer hold the position.
, more than 50 executives have left in the third quarter, according to incomplete statistics.
As of September 25, more than 180 senior executives from the domestic pharmaceutical industry will leave in 2020, involving well-known domestic pharmaceutical companies such as Hengrui Pharmaceuticals and Shandong Step, as well as multinational giants such as Novaral, GSK and Gilead.
In 2020, more than 180 senior executives will leave their jobs (Photo: Pharmaceutical Network) As of September 4, Guizhou Xinbang Pharmaceutical Co., Ltd. (hereinafter referred to as "Xinbang Pharmaceuticals") announced that the company's directors, Mr. Zhang Jieqing and Mr. Ma Wei, respectively, applied to resign as directors of the company for personal work reasons.
mr. Zhang Jieqing remained the deputy general manager of the company after he resigned as a director, and Mr. Ma still serves in the subsidiary.
September 5, Novarma announced that Novarma Pharmaceuticals Asia Pacific, Middle East and Africa (APMA) President and Novaral Group China President Yu Xudong decided to leave Novarma for personal reasons.
, Dan Brindle will take over as President of Novaral China and Iris Zemzoum will take over as President of the Asia Pacific, Middle East and Africa Region (APMA).
fact, it's not unusual for pharmaceutical companies to move at the top, but since 2020, the number of jobs in the pharmaceutical industry has been significantly denser and more concentrated than usual.
the author combed, in the first half of 2020 about 69 revenue of more than 100 million listed pharmaceutical company executives have been adjusted.
To this, some industry experts said that by the epidemic and domestic volume procurement, international cooperation and other factors such as changes in the competitive environment, many pharmaceutical enterprises suffered a decline in performance, development strategy, personnel adjustment has become frequent, which is not only the performance of enterprise management pressure, but also the transformation and upgrading of China's pharmaceutical industry is accelerating performance.
Regarding whether there will be drug executives leaving for some time to come, an unnamed pharmaceutical executive gave a positive answer: "There will certainly be drug executives leaving for some time to come."
because the pharmaceutical industry is particularly affected by policy, many pharmaceutical companies have to find a way to transform, or they will be eliminated.
in the process of transformation, far from change is inevitable.
" at present, the industry generally believes that the adjustment of talent has been the fundamental to the future survival of pharmaceutical companies.
the background of the whole industry transformation, the strategy and personnel adjustment of pharmaceutical enterprises will only become more and more frequent.
major pharmaceutical companies only timely adjustment to adapt to the new changes, and match the current stage of development of the appropriate talent, in order to survive and develop.
foreseeable, in this context, with the landing of various reform policies, the future core executives will also emerge 'departure tide', there will be more and more pharmaceutical companies to start a talent war, to join the adjustment team.